Complications of chemoembolization performed with DC Bead™ loaded with doxorubicin (DEBDOX) of diameters 100–300 μm and 300–500 μm are presented in this paper. These diameters are currently the smallest available in drug-eluting technology.
Included are 237 patients who were treated with sequential DEBDOX with doxorubicin loaded at 37.5 mg/ml of DC Bead. The National Cancer Institute Common Terminology Criteria for Adverse Events (version 3.0) were used to categorize complications.
Thirty-day mortality was 1.26% (3/237). Incidence of grade 5 complications was 1.26% (3/237). Overall, grade 4 complications resulted in 5.48% (13/237) (irreversible liver failure, cholecystitis). Grade 2 liver function deterioration developed in 10 patients (4.2%). Cholecystitis/grade 2 and 4 incidents were observed in 3.6–5.06% across sessions (overall 13 patients; 5.48%). Postembolization Syndrome (PES) grade 1 or 2 was observed in up to 86.5%; however, grade 2 was observed in 25–42.19% across treatments. Pleural effusion was seen in eight patients (overall 3.37%; grade 1 in 1.8–3.7% across treatments; grade 3 in 0.42%). Grade 1 procedure-related laboratory pancreatitis was seen in 0.45%, and grade 2 gastrointestinal bleeding was seen in 0.84%. Procedure-associated skin erythema/grade 1 was seen in 0.84%. There was no correlation of liver failure or transient liver function deterioration with the diameter of the beads (p = 0.25–0.37 and p = 0.14–0.89, respectively). Stratifying with the diameter of the beads correlation values was: for cholecystitis (p = 0.11–0.96 across treatments), PES (p = 0.35–0.83), temporary/grade 1 elevation of liver enzymes (p = 0.002–0.0001), and bilirubin (p = 0.04–0.99).
DEBDOX chemoembolization is safe and small calibres do not result in increased complication rates compared with results of series using larger diameters of beads.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Lo CM, Ngan H, Tso WK et al (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164–1171
Llovet JM, Real MI, Montana X et al (2002) Barcelona Liver Cancer Group. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial. Lancet 359:1734–1739
Cammà C, Schepis F, Orlando A et al (2002) Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 224(1):47–54
Varela M, Real MI, Burrel M et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol 46(3):474–481
Poon RN, Tso WK, Pang RWC et al (2007) A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. Clin Gastroenterol Hepatol 5:1100–1108
Malagari K, Chatzimichael K, Alexopoulou E et al (2008) Transarterial chemoembolisation of unresectable hepatocellular carcinoma (HCC) with drug eluting beads (DEB); results of an open label study of 62 patients. Cardiovasc Intervent Radiol 31:269–280
Malagari K, Alexopoulou E, Chatzimichail K et al (2008) Transcatheter chemoembolization in the treatment of HCC in patients not eligible for curative treatments: midterm results of doxorubicin-loaded DC Bead™. Abdom Imaging 33(5):512–519
Kettenbach J, Stadler A, Katzler I et al (2008) Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Intervent Radiol 31:468–476
Malagari K, Pomoni M, Kelekis A et al (2010) Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. Cardiovasc Intervent Radiol 33(3):541–551
Lammer J, Malagari K, Vogl T et al (2010) PRECISION V Investigators Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 33(1):41–52
National Cancer Institute (2003) Common terminology criteria for adverse events, version 3.0. National Cancer Institute, Bethesda, MD
Common Terminology Criteria for Adverse Events (CTCAE) v3.0, Publish Date: June 10, 2003, Notice of Modifications (March 31, 2003–June 10, 2003)
Vogl TJ, Lee C, Lencioni R et al (2010) Liver, gastrointestinal and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial ECR 2010-B241, p 311
Kim W, Clark TW, Baum RA et al (2001) Risk factors for liver abscess formation after hepatic chemoembolization. J Vasc Interv Radiol 12:965–968
Del Poggio P, Maddeo A, Zabbialini G et al (2007) Chemoembolization of hepatocellular carcinoma with drug eluting beads. J Hepatol 47:157–159
Song SY, Chung J, Han KW et al (2001) Liver abscess after transcatheter oily chemoembolization for hepatic tumors: Incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 12(3):313–320
Poon RT, Ngan H, Lo CM et al (2000) Transarterial chemoembolization for inoperable hepatocellular carcinoma and postresection intrahepatic recurrence. J Surg Oncol 73:109–114
de Baere T, Roche A, Amenabar JM et al (1996) Liver abscess formation after local treatment of liver tumors. Hepatology 23:1436–1440
Tarazov PG, Polysalov VN, Prozorovskij KV et al (2000) Ischemic complications of transcatheter arterial chemoembolization in liver malignancies. Acta Radiol 41:156–160
Chan AO, Yuen MF, Hui CK et al (2002) A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in patients with hepatocellular carcinoma. Cancer 94:1747–1752
Groupe d’Étude et de Traitment du Carcinome Hépatocellulaire (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256–1261
Chung JW, Park JH, Han JK et al (1996) Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198:33–40
Chang JM, Tzeng WS, Pan HB et al (1994) Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 74:2449–2453
Katsushima S, Inokuma T, Oi H et al (1997) Acute hepatic failure following transcatheter arterial embolization for the treatment of hepatocellular carcinoma. Digestion 58(2):189–195
Jeon SH, Park KS, Kim YH et al (2007) Incidence and risk factors of acute hepatic failure after transcatheter arterial chemoembolization for hepatocellular carcinoma. Korean J Gastroenterol 50(3):176–182
Marelli L, Stigliano R, Triantos C et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30:6–25
Lewis AL, Taylor RR, Hall B et al (2006) Pharmacokinetic and safety study of doxorubicin-eluting beads in a porcine model of hepatic arterial embolization. J Vasc Interv Radiol 17(8):1335–1343
Li X, Feng GS, Zheng CS et al (2003) Influence of transarterial chemoembolization on angiogenesis and expression of vascular endothelial growth factor and vasic fibroblast growth factor in rat with Walker-256 transplanted hepatoma: an experimental study. World J Gastroenterol 9:2445–2449
Pelletier G, Ducreux M, Gay F et al (1998) Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 29:129–134
Chen MS, Li J-Q, Zhang Y-Q et al (2002) High-dose iodized oil transcatheter arterial chemoembolization for patients with large hepatocellular carcinoma. World J Gastroenterol 8(1):74–78
Bronowicki JP, Vetter D, Dumas F et al (1994) Transcatheter oily chemoembolization for hepatocellular carcinoma: a 4-year study of 127 French patients. Cancer 74:16–24
Stefanini GF, Amorati P, Biselli M et al (1995) Efficacy of transarterial targeted treatments on survival of patients with hepatocellular carcinoma. An Italian experience. Cancer 75:2427–2434
Takenaka K, Yoshida K, Nishizaki T et al (1995) Postoperative prophylactic lipiodolization reduces the intrahepatic recurrence of hepatocellular carcinoma. Am J Surg 169:400–404
Paye F, Farges O, Dahmane M et al (1999) Cytolysis following chemoembolization for hepatocellular carcinoma. Br J Surg 86:176–180
Wigmore SJ, Redhead DN, Thomson BN et al (2003) Postchemoembolisation syndrome: tumour necrosis or hepatocyte injury? Br J Cancer 89:1423–1427
Sakamoto I, Aso N, Nagaoki K et al (1998) Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics 18(3):605–619
Nakamura H, Kondoh H (1986) Emphysematous cholecystitis: complication of hepatic arterial embolization. Cardiovasc Intervent Radiol 9:152–153
Kim HK, Chung YH, Song BC et al (2001) Ischemic bile duct injury as a serious complication after transarterial chemoembolization in patients with hepatocellular carcinoma. J Clin Gastroenterol 32:423–427
Wang MQ, Shao RH, Ye HY et al (2005) Investigation of bile duct injury after transcatheter arterial chemoembolization. Zhonghua Zhong Liu Za Zhi 27:609–612
Leung TK, Lee CM, Chen HC (2005) Anatomic and technical skill factor of gastroduodenal complication in post-transarterial embolization for hepatocellular carcinoma: a retrospective study of 280 cases. World J Gastroenterol 11:1554–1557
Brennan DDB, Farrelly CB, Cooney RB et al (2005) Abdominal rash after transarterial chemoembolization via the right inferior phrenic artery. J Vasc Interv Radiol 16(9):1269
Arora BR, Soulen BMC, Haskal ZJ (1999) Cutaneous complications of hepatic chemoembolization via extrahepatic collaterals. J Vasc Interv Radiol 10:1351–1356
Brown KT (2004) Fatal pulmonary complications after arterial embolization with 40- to 120-micro m tris-acryl gelatine microspheres. J Vasc Interv Radiol 15(21):197–200
Maluccio MA, Covey AM, Ben Porat L et al (2008) Transcatheter arterial embolization with only particles for the treatment of unresectable hepatocellular carcinoma. J Vasc Interv Radiol 19(6):862–869
Liu CL, Ngan H, Lo CM et al (1998) Ruptured hepatocellular carcinoma as a complication of transarterial oily chemoembolization. Br J Surg 85:512–514
Battula N, Madanur M, Priest O et al (2009) Spontaneous rupture of hepatocellular carcinoma: a Western experience. Am J Surg 197(2):164–167
Shin SW, Do YS, Choo SW et al (2006) Diaphragmatic weakness after transcatheter arterial chemoembolization of inferior phrenic artery for treatment of hepatocellular carcinoma. Radiology 241(2):581–583
Conflict of interest
The authors claim no conflict of interest.
About this article
Cite this article
Malagari, K., Pomoni, M., Spyridopoulos, T.N. et al. Safety Profile of Sequential Transcatheter Chemoembolization with DC Bead™: Results of 237 Hepatocellular Carcinoma (HCC) Patients. Cardiovasc Intervent Radiol 34, 774–785 (2011). https://doi.org/10.1007/s00270-010-0044-3
- Interventional oncology
- Endovascular treatment